Dr. Farshid Dayyani

Dr. Farshid Dayyani is a board-certified UCI Health medical oncologist who specializes in the treatment of gastrointestinal and hepatobiliary malignancies. His clinical interests include colorectal, esophageal, stomach, liver, bile duct, pancreatic and neuroendocrine cancers, as well as anal carcinoma.He earned a combined medical degree and PhD in immunology at Ludwig Maximilian University of Munich in Germany. He completed a research fellowship in cancer biology and an internal medicine residency at Harvard Medical School in Boston, Mass. Next, he completed a combined clinical and research fellowship in medical oncology at the University of Texas MD Anderson Cancer Center in Houston. He later served as global clinical lead for oncology at Roche Diagnostics.Dayyani serves as medical director of the Stern Center for Clinical Trials & Research and associate director for translational science for the Chao Family Comprehensive Cancer Center. His research focus is on innovative clinical and translational studies of gastrointestinal and hepatobiliary carcinomas with the goal of bringing leading-edge treatments to patients.He manages a wide portfolio of investigator-initiated, National Cancer Institute-funded and industry sponsored clinical trials aimed at developing novel treatment options and establishing new biomarkers. He is also the author or co-author of more than 100 research studies published in leading medical journals.

Dr. Dayyani is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Stomach Cancer, Familial Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Tissue Biopsy, and Endoscopy.

Dr. Dayyani is board certified in American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 8 clinical trials.